skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: A cure is a non-technical term so we need to be careful. Not to beat a dead horse (too much anyways)...Gilead is not offering a "cure" to Covid-19. Their drug was used as a treatment on USA patient 1 in Washington State, a young man who the doctors feared was dying from Covid-19. After receiving the injection he recovered almost immediately and was discharged from the hospital a few days later. Gilead's drug was entered into FDA trials and was shown to be effective for 30% of the people. While this percentage seems small the drug was considered so effective all the people on the placebo were put on the drug. Society is looking for a vaccine which will prevent people from getting Covid-19. This will likely prove more of a challenge to the health industry. Vaccines sometimes offer long term immunity but sometimes the immunity dies out - that is why we need Tetanus booster shots every 10 years or so. Dr. Fauci is on record as feeling a vaccine is "doable" by January 2021.
Publish if you feel this is useful.
Jim
Read Answer Asked by James on May 01, 2020
Q: Which Biotech and Semiconductor ETFs would you recommended, in order of preference? I do not have any exposure to these sectors.
Read Answer Asked by Satish on April 30, 2020
Q: J&J Is slipping . is this related to its not he lead candidate for Covid the Oxford group is ?
Gilead as a treatment how far will it go
Read Answer Asked by thambirajah on April 30, 2020
Q: Hello dear team,
Hope you are well and had the chance to enjoy some good weather.
What are your thoughts on this company ?
my known facts(hope they are right)
They have 5 ODD with the FDA and some of them are on the fast track to be commercialized ?
they are partner with one if not the biggest mexico pharma (which is also World wide?) for the commercialization of Cauzma ?
they recently raised something like 10 000 000 $
Everything seems to be going well and on track with the company and they have been delivering.

How do you think they could perform and in how long you think they will start to benefit from their hard work ?
how do you think this company could do in 5 years, if we do an optimistic and a pessimist scenario.

thank you for your time and response.
stay safe,
Read Answer Asked by Michael on April 30, 2020
Q: Do you have an opinion on this medical on line service? Are there others in this field that you would prefer?
Read Answer Asked by Allen on April 28, 2020
Q: We have had 10,000 shares at an avg cost of .58 cents of Medmira sitting in our portfolio for years - assuming it was pretty much a dead duck In the last few days, however, it has sprung to life quacking with an announcement of now providing C19 testing kits . I've read the news info but cannot determine if this is just a flash in the pan and we should grab the money and run. Or, is there something really here that might be a business that can bring the share price up to or past our average cost. Would appreciate your experienced eye in looking at this situation and hearing what your thoughts might be.
Many thanks as always.
Read Answer Asked by Alexandra on April 27, 2020
Q: Thoughts on the earnings released this morning?

Sales increased 21% to $35.4 million for the year-ended December 31, 2019; up 34% to $10.8 million for the fourth quarter; Sales in constant currency increased 24% for the year; 36% for the quarter.

Gross profit increased 15% to $19.0 million for the year; up 34% to $6.1 million for the quarter.

Net income of $793 thousand for the year and $931 thousand for the quarter.

Adjusted EBITDA increased 15% year over year to $7.1 million for the year; up 28% to $2.2 million for the quarter.

Organic growth was 12% for the year; 15% in constant currency. Organic growth was 17% for the quarter, 18% in constant currency.

Cash flow from operations was $6.4 million for the year, up 48%, and total cash at December 31, 2019 was $12.8 million.
Read Answer Asked by Kevin on April 23, 2020
Q: Hi 5i team
What are your top picks for Global/US health care sector ETFs that are listed on TSX , for non hedged and for hedged? Are these better to be in non registered account?
Many thanks.
Read Answer Asked by Willie on April 21, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!